Alterity to Present New Data at AAN 2024 Annual Meeting
Ticker: PRNAF · Form: 6-K · Filed: Feb 20, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: scientific-presentation, development-stage, regulatory-filing
TL;DR
**Alterity Therapeutics is presenting new data at the AAN 2024 Annual Meeting, signaling ongoing R&D progress.**
AI Summary
Alterity Therapeutics Limited (ASX: AT, NASDAQ: ATHE) announced on February 20, 2024, that it will present new data at the American Academy of Neurology (AAN) 2024 Annual Meeting. This 6-K filing indicates the company's ongoing scientific engagement and the incorporation of this report into several of its existing registration statements, including Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076). The company, a development stage enterprise, is based in Melbourne, Victoria, Australia.
Why It Matters
This announcement signals Alterity's continued progress in drug development and its commitment to sharing scientific findings, which could influence investor perception and future partnerships in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — As a development stage enterprise, Alterity Therapeutics faces inherent risks associated with clinical trials and regulatory approvals, despite positive data presentations.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant and presenter of new data
- American Academy of Neurology (AAN) 2024 Annual Meeting (event) — Venue for data presentation
- February 2024 (date) — Month of report and event
- 333-251073 (other) — Form S-8 registration statement file number
- 333-274816 (other) — Form F-3 registration statement file number
FAQ
What is the primary purpose of this 6-K filing by Alterity Therapeutics Limited?
The primary purpose of this 6-K filing is to report that Alterity Therapeutics Limited will present new data at the American Academy of Neurology (AAN) 2024 Annual Meeting, as stated in Exhibit 99.1.
Under which SEC Acts is Alterity Therapeutics Limited filing this report?
Alterity Therapeutics Limited is filing this report pursuant to Rule 13a-16 or 15d-163 under the Securities Exchange Act of 1934.
Into which existing registration statements is this Form 6-K being incorporated by reference?
This Form 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the business address of Alterity Therapeutics Limited as listed in the filing?
The business address of Alterity Therapeutics Limited is Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.
What is the former name of Alterity Therapeutics Limited and when did the name change occur?
The former name of Alterity Therapeutics Limited was PRANA BIOTECHNOLOGY LTD, and the name change occurred on January 5, 2001 (20010105).
Filing Stats: 196 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-02-20 08:00:30
Filing Documents
- ea0200236-6k_alterity.htm (6-K) — 14KB
- ea0200236ex99-1_alterity.htm (EX-99.1) — 26KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-015098.txt ( ) — 47KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity to Present New Data at the AAN 2024 Annual Meeting 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: February 20 , 2024 2